Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

INVIVYD, INC.

(IVVD)
  Report
Delayed Nasdaq  -  01:00 2022-11-25 pm EST
2.140 USD   -5.31%
11/17Invivyd Says it Teamed Up With Population Health Partners to Accelerate Clinical Development Projects
MT
11/17Invivyd, Inc. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société INVIVYD, INC.
11/17Invivyd, Inc. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Se..
AQ
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical De..
GL
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical De..
AQ
11/10INVIVYD, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
11/10Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights
GL
11/09Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference
GL
11/09Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference
AQ
11/02Invivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial ..
AQ
10/24Invivyd, Inc. : Change in Directors or Principal Officers, Regulation FD Disclosure, Finan..
AQ
10/24Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors
GL
10/24Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors
AQ
10/13Invivyd, Inc. : Change in Directors or Principal Officers, Regulation FD Disclosure, Finan..
AQ
10/13Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resourc..
GL
10/13Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resourc..
GL
10/12Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During..
GL
10/12Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During..
AQ
09/13Invivyd, Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial..
AQ
09/12Adagio Therapeutics, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/12Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Com..
GL
09/12Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Com..
AQ
09/12Adagio Therapeutics Announces Corporate Name Change to Invivyd
GL
09/12Adagio Therapeutics Announces Corporate Name Change to Invivyd
AQ
09/06Adagio Therapeutics to Participate in Upcoming Investor Conferences
GL
09/06Adagio Therapeutics to Participate in Upcoming Investor Conferences
AQ
08/15ADAGIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
08/15Adagio Therapeutics : Reports Second Quarter 2022 Financial Results and Business Highlight..
PU
08/15Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highligh..
GL
07/05Adagio Therapeutics : Announces Results of Annual Meeting of Stockholders and Evolution of..
PU
07/05Adagio Therapeutics, Inc. : Change in Directors or Principal Officers, Other Events, Finan..
AQ
07/05Mithril Capital's Ajay Royan Sends Letter Thanking Adagio Therapeutics Shareholders for..
BU
07/05Adagio Announces David Hering Named Permanent Chief Executive Officer and Director
GL
07/01Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board o..
GL
07/01Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board o..
AQ
06/30Adagio Therapeutics, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
06/22Adagio Therapeutics, Inc. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/21Adagio Therapeutics, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
06/13Adagio Therapeutics : Results from the Phase 2/3 Randomized, Double-Blind, Placebo-Control..
PU
06/13Adagio Therapeutics : ADG20, a half-life–extended monoclonal antibody in development..
PU
05/19Adagio Therapeutics : Material Event - Form 8-K
PU
05/19Adagio Therapeutics, Inc. : Other Events (form 8-K)
AQ
05/13ADAGIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
05/13Adagio Therapeutics Reports First Quarter 2022 Financial Results
GL
04/14Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request
AQ
03/31ADAGIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
03/30Adagio Therapeutics : Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to M..
PU
03/30Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to ..
AQ
03/21Adagio Therapeutics : AMENDED AND RESTATED EMPLOYMENT AGREEMENT - Form 8-K/A
PU
03/21Adagio Therapeutics : AMENDED AND RESTATED EMPLOYMENT AGREEMENT - Form 8-K
PU
03/21Adagio Therapeutics, Inc. : Change in Directors or Principal Officers, Other Events, Finan..
AQ
03/21ADAGIO THERAPEUTICS, INC. Change in Directors or Principal Officers, Financial Stateme..
AQ
03/18Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders
GL
03/18Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders
GL
03/01Adagio Therapeutics, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
02/23Adagio Therapeutics : Announces David Hering Appointed Interim Chief Executive Officer - F..
PU
02/23Adagio Therapeutics, Inc. : Change in Directors or Principal Officers, Other Events, Finan..
AQ
02/23Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer
GL
02/23Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer
GL
02/22Adagio Therapeutics : Announces CEO Succession Plan - Form 8-K
PU
02/22Adagio Therapeutics, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
02/22Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates
GL
02/22Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates
GL
02/18Adagio Therapeutics Announces CEO Succession Plan
GL
02/18Adagio Therapeutics, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
01/13Adagio Therapeutics : Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants a..
PU
01/13Adagio Therapeutics, Inc. : Regulation FD Disclosure, Other Events, Financial Statements a..
AQ
01/12Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants ..
GL
01/12Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants ..
GL
01/06Adagio Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021Adagio Therapeutics : Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against..
PU
2021Adagio Therapeutics, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
2021Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Agains..
AQ
2021Adagio Therapeutics : Reports That None of the Mutations Present in SARS-CoV-2 Variant, Om..
PU
2021Adagio Therapeutics, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
2021Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, O..
AQ
2021Adagio Therapeutics : Announces Expansion of Management Team and Board of Directors to Sup..
PU
1  2Next
Upcoming event on INVIVYD, INC.